购物车0
产品总数：60950
| 中文名称 |
Disitamab vedotin
|
|---|---|
| 中文别名 |
DISITAMAB VEDOTIN (纬迪西妥单抗 );纬迪西妥单抗
|
| 英文名称 |
Disitamab vedotin
|
| 英文别名 |
Disitamab Vedotin
|
| Cas No. |
2136633-23-1
|
| 包装储存 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 产品详情 |
Disitamab vedotin (RC48) 是一种抗体-药物偶联物 (ADC)，包含抗人表皮生长因子受体2 (HER2) 的单克隆抗体，该单克隆抗体通过可降解连接子结合到细胞毒性剂 MMAE。Disitamab vedotin 增强抗肿瘤免疫。
|
|---|---|
| 生物活性 |
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
|
| 性状 |
Solid
|
| IC50 & Target[1][2] |
HER2
|
| 体外研究(In Vitro) |
The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| ClinicalTrial |
|
| 参考文献 |
[1]. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.[2]. Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. [3]. Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with
|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
